Drugs & Targets Cue Biopharma and ImmunoScape collaborate to develop cell therapy approach for solid tumors November 14, 2025Vol.51 No.42
Drugs & Targets FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma November 07, 2025Vol.51 No.41
Drugs & Targets GSK, Empirico enter license agreement for oligonucleotide candidate to treat respiratory diseases November 07, 2025Vol.51 No.41
Drugs & Targets EMA grants GSK’227 Orphan Drug Designation for pulmonary neuroendocrine carcinoma November 07, 2025Vol.51 No.41
Drugs & Targets FDA publishes draft guidance to accelerate biosimilar development and lower costs October 31, 2025Vol.51 No.40
Drugs & Targets EC approves Keytruda combination for a head-and-neck indication October 31, 2025Vol.51 No.40
Drugs & Targets FDA approves Blenrep combination for relapsed/refractory multiple myeloma after two or more lines of therapy October 24, 2025Vol.51 No.39
Drugs & Targets CHMP adopts positive opinion for Libtayo as adjuvant treatment for high-risk CSCC October 24, 2025Vol.51 No.39
Drugs & Targets FDA requires a boxed warning for immune effector cell-associated enterocolitis following Carvykti treatment October 17, 2025Vol.51 No.38
Drugs & Targets ARPA-H selects Tempus as contract research organization for ADAPT Program October 17, 2025Vol.51 No.38
